Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR) (PETRICHOR)
3 giugno 2026 aggiornato da: AstraZeneca
PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose disease is inadequately controlled with systemic corticosteroids (SCS) and/or surgery.
Eligible participants are newly initiated on subcutaneous tezepelumab in routine clinical practice, in accordance with the European Summary of Product Characteristics (SmPC).
Treatment decisions are made jointly by patients and their physicians, independent of study enrollment.
No additional diagnostic or monitoring procedures are applied; data are collected using epidemiological methods at baseline and during routine clinical visits for up to 104 weeks.
Panoramica dello studio
Stato
Non ancora reclutamento
Tipo di studio
Osservativo
Iscrizione (Stimato)
200
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
The study population will consist of male and female participants aged ≥ 18 years treated by ear-nose-throat specialists with diagnosed severe uncontrolled CRSwNP, for whom a tezepelumab biologic treatment for CRSwNP will be initiated in line with the applicable European Summary of Product Characteristics (SmPC) within routine clinical practice.
The decision to initiate or switch to Tezepelumab must be made by the treating physician according to the participant's medical needs and a positive benefit/risk balance.
Eligible patients will be included into the study after and independently of the treating physician's treatment and diagnostic decisions.
Each participant should meet all the Inclusion Criteria and none of the Exclusion Criteria for this study in order to be part of the study.
Descrizione
Inclusion Criteria:
- - Participant must be 18 years of age or older, at the time of signing the informed consent.
- - Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1.
- - Stable standard of care (SoC) treatment with Intranasal corticosteroids (INCS) for CRSwNP for at least 30 days prior to routine care visit 1.
- - Physician decision that participant is eligible for treatment with Tezepelumab according to locally approved CRSwNP label.
- Participants must be able and willing to read and comprehend written instructions, to collect Patient-reported outcome (PROs) and medication intake via app or alternative mode (paper) and to sign the informed consent document. Use of the mobile app is optional; participants without smartphones will not be excluded. Mode of data capture will be recorded and adjusted for in analyses where relevant.
- - Participants who will be enrolled after index date need to have at least one measurement for SNOT-22 prior (within a maximum of 4 weeks) to index date.
- - -
Exclusion Criteria:
- - Participants who participate in an observational study that might influence the assessment of the current study (participants can be part of the German National Registry for Chronic rhinosinusitis (GENRE-CRS)); or participate in an interventional clinical trial in the last 3 months.
- - Concurrent biologic therapy for CRSwNP or Asthma except where the last dose was administered ≥ 30 days. Stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment) is allowed.
- - Endoscopic NP surgery within 6 months prior to index date.
- - Condition (acute or chronic) that, in the investigator's opinion, would limit the participant's ability to complete questionnaires or participate in this study.
- - History of documented anaphylactic reactions/hypersensitivity/serious allergic reactions (immune complex disease) following any biologic therapy.
- - Known hypersensitivity to Tezepelumab or any of its excipients.
- - Pregnancy, planned pregnancy or lactation period.
- - -
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean change from baseline in sino-nasal symptoms measured by SNOT-22 total score at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during each routine care visit
|
To describe changes from baseline in patient-reported sino-nasal symptoms as evaluated by Sinonasal outcome test (SNOT)-22 total score following initiation of tezepelumab treatment. SNOT-22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes). |
From Baseline up to 104 weeks, during each routine care visit
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of SNOT-22 total score responders (minimal clinically important difference (MCID) from baseline = -8.9) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe responder proportion in sino-nasal symptoms as evaluated by SNOT-22 total score following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in NB measured by VAS-NB at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal blockage (NB) as evaluated by a visual analog scale (VAS)-NB following initiation of tezepelumab treatment. VAS-NB is a 10-cm line with a bottom anchor of 0 = None and 10 = As bad as you can imagine. Participants will be requested to answer the following question: Please rate your [NB] at its worst over the previous 14 days. |
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of NB responders (minimal clinically important difference (MCID) from baseline = -3.0; in participants with VAS-NB ≥ 7 at baseline) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal blockage (NB) as evaluated by a VAS-NB following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in loss of smell score evaluated by SST-12/16.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in sense of smell as evaluated by Sniffin Sticks Test (SST)-12/16 odours following initiation of tezepelumab treatment. SST-12/16 is a validated tool to assess the chemosensory olfactory performance of an individual. The SST is based on 12 or 16 pen-like odor dispensing devices. The participant will have to name the smell using a multiple-choice form which offers 4 answers for every pen, only one of the answers is correct. Participants with a SST-16 result will be converted to the range of SST-12 results through percentage based conversion. |
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of SST-16 responders (MCID from baseline = 3) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in sense of smell as evaluated by SST-12/16 odours following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants in each category of olfactory function based on SST-12 results (normosmia 11-12, hyposmia 7-10 and anosmia 0-6) at clinical routine visits. Participants with a SST-16 result will be converted to the range of SST-12 results.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in sense of smell as evaluated by SST-12/16 odours following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in loss of smell score evaluated by VAS-Smell.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in sense of smell as evaluated by VAS-Smell following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of VAS-Smell responders (MCID from baseline = -3.0; in participants with VAS-Smell ≥ 7 at baseline) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in sense of smell as evaluated by VAS-Smell following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in NP severity as measured by VAS-NP symptoms at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal polyp (NP) severity as evaluated by VAS-NP.
The VAS-NP is a 10-cm line with a bottom anchor of 0 = None and 10 = As bad as you can imagine.
Participants will be requested to answer the following question: Please rate your [loss of smell] at its worst over the previous 14 days.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of NB responders (MCID from baseline = -3.0; in participants with VAS-NB ≥ 7 at baseline) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal polyp (NP) severity as evaluated by VAS-NP.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in total NPS evaluated by nasal endoscopy by analysing data at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal polyp score (NPS) following initiation of tezepelumab treatment. The NPS is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. Total NPS is graded based on polyp size described in Gevaert et al. 2023. (0=no polyps; 1= Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate ; 2= Polyps reaching below the lower border of the middle turbinate; 3= Polyps reaching the lower border of the inferior turbinate or a middle meatal polyp with a score of 2 with any additional polyp medial to the middle turbinate; 4= Large polyps causing complete or near complete obstruction of the inferior nasal cavity i. e., touching the floor of the nose). |
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of NPS responders (MCID from baseline = -1.0) at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe changes in nasal polyp score (NPS) following initiation of tezepelumab treatment.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the patient-reported NP control question at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe responder proportion for NP control evaluated by patient-reported NP control question following initiation of tezepelumab treatment. The NP control question was adapted from the asthma control test (ACT) and asks participants to rate how controlled their NP condition has been over the past 2 weeks. Response options are: Not controlled at all, Poorly controlled, Somewhat controlled, Well controlled, and Completely controlled. |
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in average SCS daily dose (only for long-term use) after initiating tezepelumab at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe overall prescribed systemic cortico steroids (SCS) in participants following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants who reduced/stopped using SCS (only for long-term use) after initiating tezepelumab at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visitit
|
To describe overall prescribed systemic cortico steroids (SCS) in participants following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visitit
|
|
Proportion of participants with CRSwNP-related, asthma-related and other-disease-related SCS use at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe overall prescribed systemic cortico steroids (SCS) in participants following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Mean change from baseline in average cumulative SCS use in participants at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe overall prescribed systemic cortico steroids (SCS) in participants following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants with ≥ 500, 1000 and 2000 mg cumulative SCS at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe overall prescribed systemic cortico steroids (SCS) in participants following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants who are considered as 'good' (4-5 criteria), 'moderate' (2-3 criteria) or 'no - poor response' (0-1 criteria) based on EUFOREA 2023 criteria.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe proportion of participants who show response based on European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) 2023 criteria (1: Reduced NP size (NPS), 2: Reduced need for SCS/ salvage surgery, 3: improved QoL (SNOT-22), 4: improved sense of smell (VAS-Smell or SST), 5: Reduced impact of comorbidities (ACT for asthma)) following initiation of tezepelumab.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants who reach 5 EUFOREA 2023 criteria at clinical routine visits.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe proportion of participants who show response based on EUFOREA 2023 criteria.
|
From Baseline up to 104 weeks, during clinical routine visit
|
|
Proportion of participants with AEs, SAEs.
Lasso di tempo: From Baseline up to 104 weeks, during clinical routine visit
|
To describe the safety and tolerability of tezepelumab treatment.
Safety evaluated based on type of Adverse Event (AE), intensity, causal relationship to treatment, duration, handling, outcome, and seriousness.
|
From Baseline up to 104 weeks, during clinical routine visit
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
30 giugno 2026
Completamento primario (Stimato)
31 dicembre 2029
Completamento dello studio (Stimato)
31 dicembre 2029
Date di iscrizione allo studio
Primo inviato
3 giugno 2026
Primo inviato che soddisfa i criteri di controllo qualità
3 giugno 2026
Primo Inserito (Effettivo)
8 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
3 giugno 2026
Ultimo verificato
1 maggio 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- D5242R00004
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .